A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113Drug: Placebo
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT05357755
- Locations
- 🇺🇸
Dermatology Specialists, Louisville, Kentucky, United States
🇺🇸Unity Clinical Research, Oklahoma City, Oklahoma, United States
🇩🇪Privatpraxis Dr. Hilton & Partner, Dusseldorf, Germany
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 74
- Registration Number
- NCT05338775
- Locations
- 🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Drug: NipocalimabDrug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 201
- Registration Number
- NCT05327114
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇨🇳Chifeng Municipal Hospital, Chifeng, China
🇨🇳Peking University Third Hospital, Beijing, China
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 262
- Registration Number
- NCT05316155
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Urology San Antonio Research, San Antonio, Texas, United States
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT05307692
- Locations
- 🇺🇸
Allied Biomedical Research Institute (ABRI), Inc, Miami, Florida, United States
🇺🇸Quantix Research, Miami, Florida, United States
🇺🇸Entrust Clinical Research, Miami, Florida, United States
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT05295927
- Locations
- 🇺🇸
GU Research Network, Omaha, Nebraska, United States
🇺🇸Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: JNJ-73763989Drug: PD-1 inhibitorDrug: Tenofovir DisoproxilDrug: Tenofovir AlafenamideDrug: Entecavir
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT05275023
- Locations
- 🇪🇸
Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain
🇬🇧Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom
🇫🇷Hopital Beaujon, Clichy, France
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
- Conditions
- Scalp PsoriasisPlaque Psoriasis
- Interventions
- Drug: GuselkumabDrug: Placebo
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT05272150
- Locations
- 🇺🇸
Tory P Sullivan M D PA, North Miami Beach, Florida, United States
🇨🇦Dermatology Research Institute Inc, Calgary, Alberta, Canada
🇺🇸Total Skin and Beauty Dermatology Center, Birmingham, Alabama, United States
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression
- Conditions
- Depression
- Interventions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05268497
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Sheppard Pratt Health System, Baltimore, Maryland, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05265273
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Ctr, Hershey, Pennsylvania, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States